An anti-inflammatory peptide derived from oyster protein, its screening method and application

By combining bioinformatics and molecular docking technology with the Caenorhabditis elegans model, a novel anti-inflammatory peptide, EEDWDFLPPK, was screened. This solved the problems of low efficiency and high cost in traditional methods, achieving efficient screening and validation. It showed significant anti-inflammatory effects in both in vitro and in vivo, activated the skn-1 and daf-16 signaling pathways to reduce inflammatory damage, and promoted the development of marine-derived anti-inflammatory agents.

CN123106822APending Publication Date: 2026-11-17SHANGHAI JIAOTONG UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611131357.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-29
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In existing technologies, the screening methods for anti-inflammatory peptides derived from oyster protein are inefficient and costly. There is a lack of efficient screening systems based on bioinformatics prediction and in vivo model validation. Furthermore, the high-value utilization of oyster resources is insufficient, and the systematic exploration of anti-inflammatory activities and the analysis of their mechanisms of action are inadequate.

Method used

Using bioinformatics analysis and molecular docking technology combined with an in vivo model of Caenorhabditis elegans, a novel anti-inflammatory peptide, EEDWDFLPPK, was screened out through enzymatic digestion, ultrafiltration, and reversed-phase high-performance liquid chromatography. Its activity and mechanism were then verified through in vitro cell and in vivo models.

Benefits of technology

The anti-inflammatory activity of the novel anti-inflammatory peptide EEDWDFLPPK was rapidly identified and verified. It significantly inhibited inflammatory factors in vitro and reduced inflammatory damage in vivo by activating the skn-1 and daf-16 signaling pathways, providing a development strategy for marine-derived anti-inflammatory agents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106822A_ABST
    Figure CN123106822A_ABST
Patent Text Reader

Abstract

This invention discloses an anti-inflammatory peptide derived from oyster protein, its screening method, and its application, belonging to the field of bioactive peptide technology. Highly active components were obtained by enzymatic hydrolysis of defatted Pacific oyster (Crassostrea gigas) powder with trypsin, followed by purification using ultrafiltration and reversed-phase high-performance liquid chromatography. The peptide sequence was identified using LC-MS / MS, and anti-inflammatory activity, toxicity, and allergenicity were predicted using bioinformatics tools (PreAIP, ToxinPred, AllerTOP). Molecular docking was performed targeting NF-κB and Keap1 to screen and obtain a novel anti-inflammatory peptide, EEDWDFLPPK (E10K). In vitro experiments showed that E10K (1000 μg / mL) inhibited LPS-induced NO, TNF-α, IL-1β, and IL-6 levels in RAW264.7 cells by 44.64%, 52.56%, 57.03%, and 60.62%, respectively. A Caenorhabditis elegans model confirmed that E10K can reduce paraquat-induced ROS levels (by 57.10%), repair intestinal barrier damage caused by PA14 infection (reducing the rate of leaky gut to 23.81%), extend nematode lifespan by 20.12%, and exert anti-inflammatory effects by activating the skn-1 and daf-16 signaling pathways. This invention provides a new strategy for the development of marine-derived anti-inflammatory peptides.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of bioactive peptide technology, specifically relating to an anti-inflammatory peptide derived from oyster protein, its screening method, and its application. Background Technology

[0002] Inflammation is the body's defensive response to harmful stimuli, but excessive or persistent inflammation can induce tissue damage and participate in the development of various chronic diseases such as enteritis, arthritis, and cardiovascular disease. Currently, commonly used anti-inflammatory drugs (such as nonsteroidal anti-inflammatory drugs) are prone to causing side effects such as gastrointestinal damage and liver and kidney toxicity with long-term use. Therefore, the development of safe and effective natural anti-inflammatory active ingredients has become a research hotspot.

[0003] my country is rich in oyster resources, with a production of 7.2525 million tons in 2024, accounting for more than 87% of global production. Oysters are high in protein, with a protein content of 39.1%-53.1% on a dry basis, and a complete amino acid composition, making them a high-quality raw material for the preparation of bioactive peptides. Existing research shows that oyster peptides have antioxidant, immunomodulatory, and anti-fatigue activities, but the systematic exploration and mechanism of action of their anti-inflammatory activities are still insufficient. Traditional anti-inflammatory peptide screening methods mostly rely on enzymatic digestion, repeated separation and purification, and in vitro activity determination, which are characterized by long cycles, low efficiency, and high costs. At the same time, there is a lack of efficient screening systems that integrate virtual screening, molecular docking, and in vivo model validation, making it difficult to quickly obtain highly active anti-inflammatory peptides.

[0004] Currently, there are no studies based on bioinformatics prediction, molecular docking, and *C. elegans* (C. elegans). Caenorhabditis elegans Reports have been published on the joint discovery of oyster-derived anti-inflammatory peptides using in vivo models, and the identification of their anti-inflammatory effects through the skn-1 / daf-16 signaling pathway. Summary of the Invention

[0005] Technical problem to be solved: In view of the above problems, the purpose of this invention is to provide an oyster protein-derived anti-inflammatory peptide, its screening method and application, to prepare protease hydrolysates from Pacific oysters, to rapidly identify novel anti-inflammatory peptides by combining bioinformatics analysis and molecular docking technology, and to verify their activity and mechanism through in vitro cell and Caenorhabditis elegans models, so as to provide technical support for the development of marine-derived anti-inflammatory functional products.

[0006] Technical solution: An oyster protein-derived anti-inflammatory decapeptide, wherein the amino acid sequence of the oyster protein-derived anti-inflammatory decapeptide is EEDWDFLPPK.

[0007] The present invention also provides an oyster protein-derived anti-inflammatory peptide, wherein the oyster protein-derived anti-inflammatory peptide comprises the above-mentioned oyster protein-derived anti-inflammatory decapeptide with the amino acid sequence EEDWDFLPPK.

[0008] The present invention also provides an oyster protein hydrolysate, wherein the hydrolysate contains an oyster protein-derived anti-inflammatory decapeptide or an oyster protein-derived anti-inflammatory peptide with the amino acid sequence EEDWDFLPPK (Glu-Glu-Asp-Trp-Asp-Phe-Leu-Pro-Pro-Lys).

[0009] The present invention also provides a method for preparing the above-mentioned oyster protein hydrolysate, comprising the following steps: (1) Use trypsin to enzymatically hydrolyze the defatted powder of Pacific oysters and take the supernatant; (2) The supernatant was separated by ultrafiltration using ultrafiltration membranes with molecular weight cutoffs of 3kDa and 1kDa in sequence, and the permeate was collected to obtain the oyster protein hydrolysate.

[0010] Furthermore, the defatted Pacific oyster powder is preferably degreased by steam explosion, spray drying, and supercritical CO2 extraction. Furthermore, before enzymatic hydrolysis, the defatted oyster powder is mixed with water to prepare a 1.5% suspension.

[0011] Furthermore, the enzymatic hydrolysis is performed at a pH of 7.5-8.5, a temperature of 45-55 °C, and a time of 4-5 h.

[0012] Furthermore, the enzymatic hydrolysis was performed at a pH of 8.0, a temperature of 50°C, and a time of 4.5 hours.

[0013] Furthermore, the amount of trypsin added accounts for 2.5%-3.5% of the substrate mass.

[0014] Furthermore, the amount of trypsin added is 3% of the substrate mass.

[0015] Furthermore, after the enzymatic hydrolysis was completed, the enzyme was inactivated at 100℃ for 15 min, and the supernatant was collected by centrifugation at 8000×g for 10 min.

[0016] The present invention also provides a method for screening the above-mentioned oyster protein-derived anti-inflammatory peptides, wherein the above-mentioned oyster protein hydrolysate is separated by reversed-phase high-performance liquid chromatography, and the component with the highest anti-inflammatory activity is collected to obtain the chromatographically separated component, which is the oyster protein-derived anti-inflammatory peptide.

[0017] Furthermore, the column type for the reversed-phase high-performance liquid chromatography (RP-HPLC) separation is a C18 column; the mobile phase for the RPI separation includes mobile phase A and mobile phase B, wherein mobile phase A is water and mobile phase B is methanol.

[0018] This invention also provides a method for screening anti-inflammatory decapeptides derived from oyster protein, comprising the following steps: S1: Predict the anti-inflammatory activity of the target peptide sequence and initially screen out candidate peptide sequences with potential anti-inflammatory activity; S2: Perform toxicity analysis, sensitization prediction, and water solubility analysis on candidate peptide sequences, eliminate sequences that do not meet safety requirements, and obtain optimized candidate peptide sequences; S3: The optimized candidate peptide sequences were molecularly docked with the inflammation-related targets NF-κB and Keap1, respectively. The AutoDock Vina software was used to find anti-inflammatory peptides with strong affinity and optimal conformation to the active site of the target. The peptide sequences were sorted according to the binding energy and screened to obtain the target peptide sequences. S4: The target peptide sequence was chemically synthesized and its anti-inflammatory activity was determined in vitro to verify the anti-inflammatory decapeptide.

[0019] The present invention also provides a composition comprising the above-mentioned oyster protein-derived anti-inflammatory decapeptide, oyster protein-derived anti-inflammatory peptide, or oyster protein hydrolysate.

[0020] The present invention also provides the application of the above-mentioned oyster protein-derived anti-inflammatory decapeptide, oyster protein-derived anti-inflammatory peptide, oyster protein hydrolysate or composition in the preparation of anti-inflammatory drugs.

[0021] The present invention also provides the application of the above-mentioned oyster protein-derived anti-inflammatory decapeptide, oyster protein-derived anti-inflammatory peptide, oyster protein hydrolysate or composition in the preparation of functional foods or health foods that help with antioxidation.

[0022] The present invention also provides a medicine with anti-inflammatory effect, the medicine comprising the above-mentioned oyster protein-derived anti-inflammatory decapeptide, oyster protein-derived anti-inflammatory peptide, oyster protein hydrolysate or a combination thereof.

[0023] The present invention also provides a health food that helps with anti-oxidation, the health food comprising the above-mentioned oyster protein source anti-inflammatory decapeptide, oyster protein source anti-inflammatory peptide, oyster protein hydrolysate or a combination thereof. Beneficial effects

[0024] 1. This invention is the first to isolate and purify a novel anti-inflammatory decapeptide EEDWDFLPPK (E10K) from Pacific oysters. Its inhibition rates against LPS-induced NO, TNF-α, IL-6, and IL-1β in macrophages reached 44.64%, 52.56%, 57.03%, and 60.62%, respectively. 2. This invention constructs a complete technical system of "enzymatic hydrolysis-purification-mass spectrometry identification-bioinformatics analysis-molecular docking-in vitro and in vitro verification", which can efficiently screen anti-inflammatory peptides; 3. This invention is the first to demonstrate the anti-inflammatory activity of E10K in Caenorhabditis elegans and elucidates that it exerts its anti-inflammatory effect by synergistically activating the skn-1 and daf-16 signaling pathways. Attached Figure Description

[0025] Figure 1The chromatogram of the reversed-phase high-performance liquid chromatography separation in Example 1; Figure 2 The antioxidant capacity of different chromatographically separated components in Example 1 is represented by different superscript letters, indicating significant differences between groups. p <0.05; Figure 3 Example 3 shows the in vitro antioxidant activity of different synthetic peptides; where A represents the effect of different synthetic peptides on hydroxyl radical scavenging ability; B represents the effect of different synthetic peptides on DPPH radical scavenging ability; and C represents the effect of different synthetic peptides on total antioxidant capacity. Different superscript letters represent significant differences between groups. p <0.05; Figure 4 The superscript letters represent the inhibitory effects of different synthetic peptides on TNF-α, IL-6, and IL-1β in Example 3, indicating significant differences between groups. p <0.05; Figure 5 The effects of different synthetic peptides on the motility and feeding ability of PA14-stressed nematodes in Example 4 are shown below. A represents the number of sinusoidal movements in 30 seconds; B represents the number of pharyngeal pump movements in 15 seconds; BC are the control group; MC is PA14 culture; and PC is dexamethasone at 50 μg / mL. Different superscript letters represent significant differences between groups. p <0.05; Figure 6 This section describes the effects of different synthetic peptides on the body length of PA14-stressed nematodes in Example 4. A represents a microscopic image of nematode body length; B represents quantitative analysis of body length; BC represents the control group; MC represents PA14 culture; and PC represents 50 μg / mL dexamethasone. Different superscript letters indicate significant differences between groups. p <0.05; Figure 7 This section describes the effects of different synthetic peptides on the intestinal integrity of PA14-stressed nematodes in Example 4. A shows a microscopic image of nematodes stained with brilliant blue disodium salt solution; B shows quantitative analysis of intestinal leakage in nematodes; BC represent the control group; MC represents PA14 culture; and PC represents 50 μg / mL dexamethasone. Different superscript letters represent significant differences between groups. p <0.05; Figure 8 The effect of different synthetic peptides on the lifespan of PA14 stressed nematodes in Example 4; Figure 9This diagram illustrates the effect of the synthetic peptide E10K in Example 5 on the fluorescence intensity of skn-1p::GFP and daf-16p::GFP nematodes. In the diagram, A represents the fluorescence image of skn-1p::GFP nematodes; B represents the fluorescence image of daf-16p::GFP nematodes; C represents the quantitative analysis of fluorescence intensity in skn-1p::GFP nematodes; D represents the quantitative analysis of fluorescence intensity in daf-16p::GFP nematodes; BC represents the control group; MC represents PA14 culture. Different superscript letters represent significant differences between groups. p <0.05; Figure 10 The image shows the KEGG enrichment annotation analysis in Example 5; where A represents the control group vs. the model group; B represents the model group vs. the sample group; the control group was cultured in OP50; the model group was cultured in PA14; and the sample group was cultured in PA14 with the addition of synthetic peptide E10K intervention. Detailed Implementation

[0026] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention. In the present invention, unless otherwise specified, the equipment and raw materials used can be purchased from the market or are commonly used in the art. Unless otherwise specified, the methods in the following embodiments are conventional methods in the art.

[0027] Example 1 The steps for isolating, purifying, and identifying oyster anti-inflammatory peptides are as follows: 1. Raw material pretreatment: Take Pacific oysters ( Crassostrea gigas Oyster meat was subjected to steam explosion (1.6 MPa, 6 min), spray drying (inlet air 198℃, outlet air 82℃), and supercritical fluid extraction for defatting (pressure 35 MPa, temperature 40℃) to obtain defatted oyster powder. The protein content was determined to be 63.39%, and the fat content was 3.10%.

[0028] 2. Enzymatic hydrolysis process optimization: Trypsin was used as the hydrolytic enzyme, and the process conditions were: enzyme dosage 3%, substrate concentration 1.5%, temperature 50℃, pH 8.0, and hydrolysis time 4.5 h.

[0029] Under these conditions, the measured degree of hydrolysis was 35.83%. The enzymatic hydrolysis product was centrifuged (8000×g, 10 min), and the supernatant was collected and lyophilized for later use.

[0030] 3. Separation and purification: (1) Ultrafiltration fractionation: The above enzymatic hydrolysate was sequentially passed through 3 kDa and 1 kDa ultrafiltration membranes, and the permeate fraction (UOP1) with a molecular weight cutoff of 1 kDa was collected. At a concentration of 50 mg / mL, this fraction had a hydroxyl radical scavenging rate of 99.35%; at a concentration of 80 mg / mL, the total antioxidant capacity was 6.111 mM Fe²⁺; and at 1000 μg / mL, it inhibited LPS-induced NO production in RAW264.7 cells by 19.59%.

[0031] (2) Reversed-phase high-performance liquid chromatography purification: The UOP1 fraction was separated using an XPT3 semi-preparative column. The mobile phase A was water and B was methanol. The elution program was: 0-2 min, 1% B; 2-10 min, 1%-50% B; 10-15 min, 50% B; 15-20 min, 50%-1% B; flow rate: 0.6 mL / min; detection wavelength: 210 nm; five major chromatographic peaks (F1-F5) were collected, and their elution chromatograms are shown below. Figure 1 As shown in the figure. Among them, the F5 component, which is the most hydrophobic, exhibits the best activity, such as... Figure 2 As shown, at a concentration of 2 mg / mL, the DPPH radical scavenging rate was 61.85%, the hydroxyl radical scavenging rate was 29.11%, and the NO generation inhibition rate was 42.89% at a concentration of 1 mg / mL.

[0032] 4. Peptide sequence identification: LC-MS / MS analysis was performed on the F5 fraction, and a total of 16,210 peptides were identified, mainly small peptides with 3-6 amino acid residues, with molecular weights mostly between 500-1000 Da, and also a small number of larger molecular weight peptides with 7-10 peptides.

[0033] Example 2 The virtual screening and molecular docking steps for oyster anti-inflammatory peptides are as follows: 1. Bioinformatics screening: The 16,210 peptides identified in Example 1 were used to predict their anti-inflammatory activity using the PreAIP tool. ToxinPred and AllerTOP were used to predict their toxicity and allergenicity. The results are shown in Table 1. A total of 17 non-toxic, non-allergenic, and novel candidate anti-inflammatory peptides were screened.

[0034] Table 1. Results of Bioinformatics Analysis

[0035] Note: The molecular weight of some peptides in the table is slightly higher than 1000 Da. This is because the ultrafiltration membrane has a certain molecular weight distribution transition region, which is related to the pore size distribution of the membrane material. This is a normal phenomenon in membrane separation technology. The anti-inflammatory activity value is the anti-inflammatory probability value predicted by the PreAIP tool, ranging from 0 to 1. The closer it is to 1, the higher the anti-inflammatory activity.

[0036] 2. Molecular docking: The key inflammatory receptor NF-κB (PDB ID: 2O61) and the key oxidative stress receptor Keap1 (PDB ID: 2FLU) were selected as targets, and molecular docking was performed using AutoDock Vina software. The results are shown in Table 2. The binding energies of the candidate peptide EEDWDFLPPK (E10K) to NF-κB and Keap1 were -7.4 kcal / mol and -8.7 kcal / mol, respectively, both below -5.0 kcal / mol, indicating stable binding. Visualization analysis showed that E10K forms 11 hydrogen bonds with amino acid residues such as Arg-56 and Ser-240 on the NF-κB receptor, and 12 hydrogen bonds with amino acid residues such as Arg-326 and Val-606 on the Keap1 receptor, demonstrating excellent binding modes.

[0037] Table 2 Binding energies of different anti-inflammatory peptides to target receptors

[0038] Example 3 The in vitro anti-inflammatory activity of oyster protein-derived anti-inflammatory decapeptide (E10K) was validated as follows: 1. Peptide synthesis: E10K was synthesized by a biotechnology company using solid-phase synthesis, with a purity >95%.

[0039] 2. Antioxidant Activity: The antioxidant capacity was determined as follows: Sample solutions of 50, 40, 30, 20, and 10 mg / mL were accurately prepared. Vitamin C was used as a positive control. The absorbance was measured at 517 nm and 510 nm, respectively, following the procedures of the DPPH free radical scavenging kit and the hydroxyl free radical scavenging kit, and the scavenging rate was calculated. The total antioxidant capacity was measured at 593 nm, following the procedures of the total antioxidant capacity kit, and the total antioxidant capacity was calculated. Results are as follows: Figure 3 As shown, at a concentration of 10 mg / mL, E10K exhibited a DPPH radical scavenging rate of 67.98 ± 1.09%, a hydroxyl radical scavenging rate of 45.34 ± 1.27%, and a total antioxidant capacity of 2.27 mM Fe. 2+ .

[0040] 3. Cellular anti-inflammatory activity: (1) Safety evaluation: RAW264.7 cells were injected at a rate of 10 per well. 5Cells were seeded in 96-well plates and cultured at 37 ℃ in a 5% CO2 incubator for 24 h until adherence. The culture medium was discarded. 100 μL of medium containing E10K (concentration gradients of 12.5, 25, 50, 100, 200, 500, 1000, and 2000 μg / mL) was added to each sample group, while an equal volume of medium without sample was added to the control group (BC). Each group was divided into 6 replicates. After culturing for another 24 h, 100 μL of 10% CCK-8 solution was added to each well, and the cells were incubated in the dark for 1 h. The absorbance was measured at 450 nm, and cell viability (%) was calculated. The CCK-8 assay showed that E10K was not cytotoxic to RAW264.7 cells in the concentration range of 12.5–1000 μg / mL.

[0041] (2) Inhibition of inflammatory factors: RAW264.7 cells were stored at 10 cells per well. 5 Cells were seeded in 96-well plates and cultured at 37 ℃ in a 5% CO2 incubator for 24 h until adherence. Cells were then divided into control (BC), model (MC), positive control (PC), and sample (E10K) groups. 100 μL of culture medium was added to each well of the BC group; 100 μL of culture medium was added to each well of the MC group; 100 μL of culture medium containing 50 μg / mL dexamethasone was added to each well of the PC group; and 100 μL of culture medium containing E10K (100, 250, 500, and 1000 μg / mL) was added to each well of the sample groups, with 6 replicates per group. After 12 h of intervention, except for the BC group, 100 μL of LPS solution (final concentration 1 μg / mL) was added to each well of the MC, PC, and sample groups, while the BC group received an equal volume of culture medium. Cells were cultured for another 24 h. Cells were collected in centrifuge tubes, centrifuged at 2500×g for 15 min, and the supernatant was collected. NO content was determined using the NO kit, with absorbance measured at 540 nm, and the NO content was calculated. TNF-α, IL-6, and IL-1β content were determined using the corresponding ELISA kits, with absorbance measured at 450 nm, and the levels of each cytokine were calculated. Results are as follows: Figure 4 As shown, E10K (1000 μg / mL) significantly inhibited the production of inflammatory factors. Compared with the model group, NO content decreased from 43.30 μM to 23.97 μM (inhibition rate 44.64%); TNF-α content decreased from 804.90 pg / mL to 381.88 pg / mL (inhibition rate 52.56%); IL-1β content decreased from 278.31 pg / mL to 109.60 pg / mL (inhibition rate 60.62%); and IL-6 content decreased from 81.94 pg / mL to 35.21 pg / mL (inhibition rate 57.03%).

[0042] (3) Improvement of cell morphology: Cell morphology was observed and photographed under a microscope (10× eyepiece, 20× objective). Microscopic observation showed that after LPS induction, RAW264.7 cells changed from round to spindle-shaped, and pseudopodia increased. After E10K treatment, cell morphology was significantly restored, the surface became smoother, and pseudopodia decreased.

[0043] Example 4 The in vivo anti-inflammatory activity evaluation (nematode model) of oyster protein-derived anti-inflammatory decapeptide (E10K) is as follows: 1. Toxicity Evaluation: Sample solutions with concentrations of 10, 100, and 1000 μg / mL were accurately prepared using sterile water and filtered through a 0.22 μm filter membrane. The sample solutions were dropped onto OP50 bacterial growth in the center of NGM medium, and synchronized nematode eggs were added. The mixture was incubated at 20 °C for 48 h. Once the nematodes reached the L4 stage, the proportion of nematodes in the L4 stage was counted. The results showed that within the concentration range of 10–1000 μg / mL, E10K had no significant effect on the growth and development of nematodes, indicating good safety.

[0044] 2. Antioxidant stress capacity: Nematodes in each group were cultured to the L4 stage on OP50 plates. Except for the control group, all groups were treated with 100 mM paraquat for 2 h. Then, L4-stage nematodes were stained with a 50 μM DHE staining solution prepared with M9 for 1 h. They were then transferred to agar-coated slides, and 1 mg / mL levamisole solution was added to anesthetize the nematodes. The samples were then photographed under a fluorescence microscope. The sample size was n=21. The results showed that the ROS fluorescence intensity in the 1000 μg / mL E10K treatment group was reduced by 57.10% compared to the MC group (100 mM paraquat), significantly alleviating oxidative damage.

[0045] 3. Anti-inflammatory and physiological function improvement: An inflammation model was constructed by infecting nematodes with Pseudomonas aeruginosa (PA14).

[0046] (1) Motion and feeding ability: Nematodes from each group were cultured to stage L4 on OP50 plates. All L4 stage nematodes (excluding the control group) were then cultured on PA14 plates at 25 °C for 24 h. Afterward, the nematodes were transferred to sterile NGM and allowed to stand for 1 min until their behavior stabilized. They were then observed under a microscope. The number of head movements within 30 s was counted to determine motility; the number of pharyngeal pumping movements within 15 s was counted to determine feeding ability (nematode sample size n=15). Figure 5 As shown, after treatment with E10K (1000 μg / mL), the number of sinusoidal movements of nematodes within 30 s recovered from 16 in the model group to 22, and the number of pharyngeal pumping movements within 15 s recovered from less than 50 to 60, which is close to that of the positive drug group.

[0047] (2) Body length and intestinal integrity: Nematodes from each group were cultured to the L4 stage on PA14, and then each group of nematodes was picked onto a glass slide, anesthetized with 1 mg / mL levamisole solution, photographed under a microscope, and the body length of the nematodes was measured (nematode sample size n=21). Nematodes from each group were cultured to the L4 stage on OP50, and L4 stage nematodes from each group except the control group were cultured on PA14 at 25 °C for 24 h. A 10% edible brilliant blue disodium salt solution was prepared with M9 and mixed with an equal volume of OP50 to prepare a mixed staining solution for later use. The nematodes were washed off the surface of the culture medium with M9 and collected in 1.5 mL centrifuge tubes. After natural sedimentation, the supernatant was discarded, and the nematodes were resuspended with an appropriate amount of M9 repeatedly until the supernatant was clear. Add an appropriate amount of staining solution, gently shake to resuspend the nematodes, stain at 20°C for 5 h, centrifuge and discard half of the supernatant, add M9, repeat until the supernatant changes from blue to colorless, indicating that the staining solution has been completely removed. Transfer the nematodes to a glass slide covered with agar, photograph them under a microscope, and count the extent of intestinal leakage (nematode sample size n=21). Results are as follows... Figure 6 and Figure 7 As shown, E10K treatment restored the body length of nematodes from 387.73 μm in the model group to 543.62 μm, repaired the intestinal barrier damage caused by PA14, and reduced the proportion of leaky nematodes from 76.19% to 23.81%.

[0048] (3) Extended lifespan: Nematodes from each group were cultured to stage L4 on OP50 plates. All L4-stage nematodes from each group (excluding the control group) were then cultured on PA14 plates. The number of dead nematodes in each group was counted every 12 hours, and a nematode survival curve was plotted. The nematode sample size was n=30. Figure 8 As shown, E10K (1000 μg / mL) treatment can extend the average lifespan of PA14-infected nematodes from 60.27 h to 72.40 h, an increase of 20.13%.

[0049] Example 5 The anti-inflammatory mechanism of oyster protein-derived anti-inflammatory decapeptide (E10K) is studied as follows: 1. Signal path verification: (1) Experiments were conducted using transgenic nematodes of skn-1p::GFP and daf-16p::GFP. The skn-1p::GFP and daf-16p::GFP nematodes of each group were cultured to the L4 stage on OP50 plates. All L4 stage nematodes (excluding the control group) were then cultured on PA14 plates at 25 °C for 24 h. After washing with M9, the nematodes were transferred to agar-coated slides, and 1 mg / mL levamisole solution was added to anesthetize them. The slides were then photographed under a fluorescence microscope (nematode sample size n=15). Figure 9As shown, PA14 infection decreased the fluorescence intensity of GFP in nematodes. After treatment with E10K (1000 μg / mL), the fluorescence intensity of skn-1p::GFP nematodes recovered from 5.60 to 10.82, and the fluorescence intensity of daf-16p::GFP nematodes recovered from 7.57 to 13.52, indicating that E10K can significantly activate the expression of skn-1 and daf-16 genes.

[0050] (2) In nematodes with defects in skn-1 and daf-16 genes, the life-extending effect of E10K was greatly weakened, with lifespans extended by only 3.46% and 9.82%, respectively, confirming that the anti-inflammatory effect of E10K depends on the skn-1 and daf-16 pathways.

[0051] 2. Transcriptomics analysis: Transcriptome sequencing was performed on nematodes from the control group, model group (PA14), and E10K-treated group. For example... Figure 10 As shown, KEGG enrichment analysis revealed that differentially expressed genes in the E10K-treated group were significantly enriched in the MAPK signaling pathway, calcium signaling pathway, and glutathione metabolism pathway. Further analysis revealed that E10K downregulated the expression of negatively regulated genes age-1 and akt-2, and upregulated the expression of antioxidant target genes sod-3, gst-4, and ctal-2. These results confirm at the transcriptional level that E10K exerts its anti-inflammatory and antioxidant effects through the synergistic regulation of the skn-1 and daf-16 pathways.

[0052] This invention establishes a highly efficient screening system for anti-inflammatory peptides from Pacific oysters, combining enzymatic hydrolysis, chromatographic separation, virtual screening, and nematode model validation. This system addresses the problems of low efficiency, high cost, and insufficient high-value utilization of oyster resources associated with traditional methods. A novel anti-inflammatory peptide, EEDWDFLPPK (E10K), was identified for the first time. In vitro experiments confirmed its significant antioxidant and anti-inflammatory activities with good stability. In vivo nematode model analysis further validated that it can alleviate oxidative stress and inflammatory damage by activating the skn-1 and daf-16 pathways. This research provides a new strategy for the development of marine-derived natural anti-inflammatory agents and offers theoretical and raw material support for the research and development of related functional foods or drugs.

[0053] In summary, this invention not only has high application prospects and social benefits, but also provides new ideas for the further research and development of marine-derived anti-inflammatory peptides, and has important scientific significance and economic value.

[0054] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention in any way. Any person skilled in the art can make many possible variations and modifications to the technical solutions of the present invention, or modify them into equivalent embodiments, without departing from the spirit and technical essence of the present invention. Therefore, any simple modifications, equivalent substitutions, equivalent changes, and modifications made to the above embodiments based on the technical essence of the present invention, without departing from the content of the technical solutions of the present invention, shall still fall within the scope of protection of the present invention.

Claims

1. An oyster protein-derived anti-inflammatory decapeptide, characterized in that, The amino acid sequence of the oyster protein-derived anti-inflammatory decapeptide is EEDWDFLPPK.

2. An oyster protein-derived anti-inflammatory peptide, characterized in that, The oyster protein-derived anti-inflammatory peptide includes the oyster protein-derived anti-inflammatory decapeptide with the amino acid sequence EEDWDFLPPK as described in claim 1.

3. An oyster protein hydrolysate, characterized in that, The enzymatic hydrolysate contains either the oyster protein-derived anti-inflammatory decapeptide with the amino acid sequence EEDWDFLPPK as described in claim 1, or the oyster protein-derived anti-inflammatory peptide as described in claim 2.

4. A method for preparing the oyster protein hydrolysate according to claim 3, characterized in that, Includes the following steps: (1) Use trypsin to enzymatically hydrolyze the defatted powder of Pacific oysters and take the supernatant; (2) The supernatant was separated by ultrafiltration using ultrafiltration membranes with molecular weight cutoffs of 3kDa and 1kDa in sequence, and the permeate was collected to obtain the oyster protein hydrolysate.

5. A method for screening the oyster protein-derived anti-inflammatory peptides of claim 2, characterized in that, The oyster protein hydrolysate described in claim 3 was subjected to reversed-phase high-performance liquid chromatography (RP-HPLC) separation, and the component with the highest anti-inflammatory activity was collected to obtain the chromatographically separated component, which is an oyster protein-derived anti-inflammatory peptide.

6. A method for screening oyster protein-derived anti-inflammatory decapeptides, characterized in that, Includes the following steps: S1: Predict the anti-inflammatory activity of the target peptide sequence and initially screen out candidate peptide sequences with potential anti-inflammatory activity; S2: Perform toxicity analysis, sensitization prediction, and water solubility analysis on candidate peptide sequences, eliminate sequences that do not meet safety requirements, and obtain optimized candidate peptide sequences; S3: The optimized candidate peptide sequences were molecularly docked with the inflammation-related targets NF-κB and Keap1, respectively. The AutoDock Vina software was used to find anti-inflammatory peptides with strong affinity and optimal conformation to the active site of the target. The peptide sequences were sorted according to the binding energy and screened to obtain the target peptide sequences. S4: The target peptide sequence was chemically synthesized and its anti-inflammatory activity was determined in vitro to verify the anti-inflammatory decapeptide.

7. A composition, characterized in that, The composition comprises the oyster protein-derived anti-inflammatory decapeptide of claim 1, the oyster protein-derived anti-inflammatory peptide of claim 2, or the oyster protein hydrolysate of claim 3.

8. The use of the oyster protein-derived anti-inflammatory decapeptide of claim 1, the oyster protein-derived anti-inflammatory peptide of claim 2, the oyster protein hydrolysate of claim 3, or the composition of claim 7 in the preparation of anti-inflammatory drugs.

9. The use of the oyster protein source anti-inflammatory decapeptide of claim 1, the oyster protein source anti-inflammatory peptide of claim 2, the oyster protein hydrolysate of claim 3, or the composition of claim 7 in the preparation of functional foods or health foods that help with antioxidation.

10. A drug with anti-inflammatory effects, characterized in that, The drug comprises the oyster protein-derived anti-inflammatory decapeptide of claim 1, the oyster protein-derived anti-inflammatory peptide of claim 2, the oyster protein hydrolysate of claim 3, or the composition of claim 7.